Dr. Shaliender Bhatia and his team recently published the results of that first-in-human, proof-of-concept pilot study in the journal Clinical Cancer Research. They reported that after G100 intra-tumoral injection, anti-tumor responses were enhanced in several patients and that five out of 10 patients experienced tumor regression, including one complete response. As of publication, all 10 patients are alive and undergoing follow-up treatment or monitoring.
Fred Hutch News Service Nov. 28, 2018
Investigators are hopeful that CMB305, a vaccine that boosts the immune response to tumor cells expressing the antigen NY-ESO-1, can improve survival outcomes for patients with synovial sarcoma, a rare subtype of soft tissue sarcoma that primarily develops…
onclive.com. Jun. 26, 2018
Seth M. Pollack, MD, of the Fred Hutchinson Cancer Research Center, discusses immunotherapy for sarcoma, including Immune Design’s immunotherapy for synovial sarcoma, and how varying microenvironments in sarcoma subtypes impact response to immunotherapy.
ASCO Daily News. Jan. 22, 2018
Doctors have created a vaccine that is showing some impressive results in a phase one trial, with few minor side effects.
Ivanhoe Broadcast News – Medical Breakthroughs. December 12, 2017
Three years ago she was out of options to treat her advanced cancer. Then, she enrolled in an immunotherapy clinical trial.
Fred Hutch News Service. September 8, 2017
Novel Targets Podcast. Bringing Science to Life. September 1, 2017
MarketWatch. August 28, 2017
‘Exciting’ results from early trial spurts further development of novel vaccine for sarcoma
Fred Hutch News Service. June 2, 2017
In a small sarcoma trial, signs of immune attack after injections of a bacteria-inspired drug
Fred Hutch News Service. April 3, 2017
Doctors are trying – with some success – to recruit the immune system to help with the war on cancer
The Economist. June 6, 2015